Evercore ISI analyst Liisa Bayko downgraded Savara (SVRA) to In Line from Outperform with a price target of $5, down from $7, after the company narrowed timelines for completion of the rolling BLA submission for Molbreevi in aPAP to the end of Q1 of 2025 from the first half. Assuming all goes well, this puts Savara on track for approval by the year-end 2025 assuming priority review and, if approved, the firm believes that Phase 3 IMPALA-2 data should support “a $500M+ product.” After having updated its model, adding expenses in preparation for launch, the firm’s target is now lower and its rating is In Line.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter